The global Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market is expected to garner a market value of US$ 3 Billion in 2023 and is expected to accumulate a market value of US$ 4.89 Billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for Focal Segmental Glomerulosclerosis (FSGS) Therapeutics registered a CAGR of 3.5% in the historical period 2018 to 2022.
The Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market is a segment of the healthcare industry that deals with the effective management of the condition. The market is expected to grow significantly in the coming years due to the increasing prevalence of the condition worldwide. The therapeutics market for FSGS is relatively small, given the rare nature of the disease. There are a few treatment options available that can help manage the symptoms and slow the progression of the disease.
One of the main treatments for FSGS is corticosteroids, such as prednisone, which can help reduce inflammation in the kidneys and decrease proteinuria. Another commonly used treatment is immunosuppressive drugs, such as cyclosporine, which can help control the immune system and reduce kidney damage.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 3 Billion |
| Anticipated Forecast Value (2033) | US$ 4.89 Billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Focal Segmental Glomerulosclerosis (FSGS) Therapeutics reflected a value of 3.5% during the historical period, 2018 to 2022. Despite the small market size, the FSGS therapeutics market is expected to grow in the coming years due to increasing awareness of the disease, advances in genetic testing and precision medicine, and the development of new therapies.
Factors such as increasing prevalence of Focal Segmental Glomerulosclerosis (FSGS), increasing prevalence of FSGS, advancements in research and development, government initiatives, growing awareness of FSGS, favorable reimbursement policies for FSGS therapeutics in many countries, and increasing investment in healthcare globally, with pharmaceutical companies investing in the research and development of FSGS therapeutics are expected to drive market growth during this period.
Moreover, strategic collaborations, mergers and acquisitions, and product innovations are expected to further drive the growth of the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market. Key players in the market are investing in R&D activities to develop new treatment options and improve the efficacy of existing ones. The market offers growth opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers.
Overall, the market for Focal Segmental Glomerulosclerosis (FSGS) Therapeutics is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Growing Awareness along with Increasing Prevalence of Focal Segmental Glomerulosclerosis (FSGS) to drive growth
One of the main factors is the increasing prevalence of FSGS worldwide. According to the National Institutes of Health (NIH), FSGS is a rare disease, affecting 7.5 per million people in the United States. However, the incidence of FSGS is increasing, especially in certain ethnic groups, such as African Americans and Hispanics.
In addition to the increasing prevalence of FSGS, advances in research and development are leading to the development of new treatments and therapies for the disease. There are several experimental drugs and therapies being developed for the treatment of FSGS, including monoclonal antibodies, stem cell therapy, and genetic therapies. These new treatments offer hope to patients with FSGS and are expected to contribute to the growth of the market.
Another factor contributing to the growth of the FSGS therapeutics market is increasing awareness and education about the disease. As more information becomes available about FSGS, healthcare providers are better equipped to diagnose and treat the disease. Patients and their families are also becoming more informed about FSGS, which can lead to earlier diagnosis and treatment.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
Currently, there are limited treatment options available for Focal Segmental Glomerulosclerosis (FSGS), and none of them are universally effective. Many of the new treatments and therapies for FSGS are expensive, which can limit access to care for some patients. This can be particularly challenging for patients who do not have adequate health insurance coverage or cannot afford the out-of-pocket expenses.
Overall, FSGS is a rare disease, and the patient population is relatively small. This can make it challenging for pharmaceutical companies to invest in developing new treatments and therapies due to the limited potential market.
Increasing awareness and diagnosis of the condition Shaping Landscape for Focal Segmental Glomerulosclerosis (FSGS) Therapeutics in South & East Asia
The Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market in the South & East Asia region is showing significant growth in recent years. This growth is driven by several factors, including the increasing prevalence of FSGS in the region, rising awareness of the disease among patients and healthcare providers, and advances in research and development.
In the South & East Asia region, the prevalence of FSGS is relatively high, especially in countries such as China, India, and Japan. This high prevalence is due to factors such as genetic predisposition, lifestyle changes, and increasing rates of chronic kidney disease in the region.
The increasing awareness of FSGS among patients and healthcare providers is also driving the growth of the market in the South & East Asia region. As more information becomes available about the disease, healthcare providers are better equipped to diagnose and treat the disease, which can lead to improved patient outcomes.
Furthermore, there has been significant progress in research and development of FSGS therapeutics in the South & East Asia region. Several pharmaceutical companies in the region are investing in the development of new drugs and therapies for the treatment of FSGS. For example, Japan-based Kyowa Kirin has developed a monoclonal antibody for the treatment of FSGS, which is expected to be launched in the region soon.
However, there are also challenges in the South & East Asia FSGS therapeutics market. These challenges include limited access to healthcare and expensive treatment options, which can limit patient access to care. Moreover, the lack of awareness of FSGS among the general public and healthcare providers in some countries can also hinder the growth of the market.
Overall, the FSGS therapeutics market in the South & East Asia region is expected to grow significantly in the coming years due to the increasing prevalence of FSGS and the growing awareness of the disease. The region's focus on research and development in FSGS therapeutics also offers opportunities for growth in the market.
Increasing Focus on Technological advancements Shaping Landscape for Focal Segmental Glomerulosclerosis (FSGS) Therapeutics in North America
North America has a relatively high prevalence of FSGS, with the disease being the leading cause of nephrotic syndrome in adults. The high prevalence of FSGS in North America is driving the demand for effective FSGS therapeutics. The region has a well-established research and development infrastructure that is constantly driving innovation in FSGS therapeutics. There have been significant advancements in the understanding of FSGS and its underlying mechanisms, leading to the development of new and effective therapies.
In addition to this, with the increasing awareness of FSGS among healthcare professionals and patients, there is a growing demand for effective FSGS therapeutics in North America. The increasing awareness has led to improved diagnosis and treatment of FSGS, leading to better patient outcomes.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Immunosuppressive agents segment to hold a significant share and push market growth
Based on current trends and ongoing clinical trials, the immunosuppressive agents segment is likely to account for a significant share of the FSGS therapeutics market. Immunosuppressive agents such as calcineurin inhibitors and mycophenolate mofetil have been shown to be effective in managing FSGS in some patients. Additionally, there are several ongoing clinical trials evaluating new immunosuppressive agents for the treatment of FSGS, which is expected to further boost this segment's growth.
Moreover, the monoclonal antibody segment is also expected to gain traction in the FSGS therapeutics market. A monoclonal antibody called rituximab has shown promise in treating some FSGS patients who do not respond to conventional therapy. The development of new monoclonal antibodies for FSGS is also underway, which is expected to drive the growth of this segment.
Key players in the market include companies such as Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc along with healthcare providers and technology companies among other global players.
The NDA submission for sparsentan is based on results from the ongoing Phase 3 PROTECT Study, which is one of the largest interventional studies conducted in IgAN to date. The study evaluated sparsentan in 404 patients with persistent proteinuria and met its pre-specified interim primary efficacy endpoint, which measured changes in proteinuria compared to the active control irbesartan.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 3 Billion |
| Market Value in 2033 | US$ 4.89 Billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled | Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc |
| Customization | Available Upon Request |
The market is valued at US$ 3 Billion in 2023.
Competition Deep Dive, Beckman Coulter Inc., and Baxter International Inc., are key market players.
Immunosuppressive agents are likely to remain preferred through 2033.
The United States market is estimated to dominate the industry with a CAGR of 4.9% during the forecast period.
The market is forecasted to register a CAGR of 5% through 2033.
1. Executive Summary | Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033 5.3.1. Primary FSGS 5.3.2. Secondary FSGS 5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 6.3.1. Corticosteroids 6.3.2. Immunosuppressive Drugs 6.3.3. Plasmapheresis 6.3.4. ACE Inhibitors and ARBs 6.3.5. Diuretics 6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Treatment , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment , 2023 to 2033 7.3.1. Drug Therapy 7.3.2. Dialysis 7.3.3. Kidney Transplant 7.4. Y-o-Y Growth Trend Analysis By Treatment , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Treatment , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Disease Type 9.2.3. By Drug Class 9.2.4. By Treatment 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Disease Type 9.3.3. By Drug Class 9.3.4. By Treatment 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Disease Type 10.2.3. By Drug Class 10.2.4. By Treatment 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Disease Type 10.3.3. By Drug Class 10.3.4. By Treatment 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. U.K. 11.2.1.2. Spain 11.2.1.3. Germany 11.2.1.4. Italy 11.2.1.5. France 11.2.1.6. Rest of Europe 11.2.2. By Disease Type 11.2.3. By Drug Class 11.2.4. By Treatment 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Disease Type 11.3.3. By Drug Class 11.3.4. By Treatment 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Indonesia 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Disease Type 12.2.3. By Drug Class 12.2.4. By Treatment 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Disease Type 12.3.3. By Drug Class 12.3.4. By Treatment 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Disease Type 13.2.3. By Drug Class 13.2.4. By Treatment 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Disease Type 13.3.3. By Drug Class 13.3.4. By Treatment 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Disease Type 14.2.3. By Drug Class 14.2.4. By Treatment 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Disease Type 14.3.3. By Drug Class 14.3.4. By Treatment 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. South Africa 15.2.1.2. GCC Countries 15.2.1.3. Rest of Middle East and Africa 15.2.2. By Disease Type 15.2.3. By Drug Class 15.2.4. By Treatment 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Disease Type 15.3.3. By Drug Class 15.3.4. By Treatment 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. U.S. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Disease Type 16.1.2.2. By Drug Class 16.1.2.3. By Treatment 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Disease Type 16.2.2.2. By Drug Class 16.2.2.3. By Treatment 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Disease Type 16.3.2.2. By Drug Class 16.3.2.3. By Treatment 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Disease Type 16.4.2.2. By Drug Class 16.4.2.3. By Treatment 16.5. U.K. 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Disease Type 16.5.2.2. By Drug Class 16.5.2.3. By Treatment 16.6. Spain 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Disease Type 16.6.2.2. By Drug Class 16.6.2.3. By Treatment 16.7. Germany 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Disease Type 16.7.2.2. By Drug Class 16.7.2.3. By Treatment 16.8. Italy 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Disease Type 16.8.2.2. By Drug Class 16.8.2.3. By Treatment 16.9. France 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Disease Type 16.9.2.2. By Drug Class 16.9.2.3. By Treatment 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Disease Type 16.10.2.2. By Drug Class 16.10.2.3. By Treatment 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Disease Type 16.11.2.2. By Drug Class 16.11.2.3. By Treatment 16.12. Indonesia 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Disease Type 16.12.2.2. By Drug Class 16.12.2.3. By Treatment 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Disease Type 16.13.2.2. By Drug Class 16.13.2.3. By Treatment 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Disease Type 16.14.2.2. By Drug Class 16.14.2.3. By Treatment 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Disease Type 16.15.2.2. By Drug Class 16.15.2.3. By Treatment 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Disease Type 16.16.2.2. By Drug Class 16.16.2.3. By Treatment 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Disease Type 16.17.2.2. By Drug Class 16.17.2.3. By Treatment 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Disease Type 16.18.2.2. By Drug Class 16.18.2.3. By Treatment 16.19. South Africa 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Disease Type 16.19.2.2. By Drug Class 16.19.2.3. By Treatment 16.20. GCC Countries 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Disease Type 16.20.2.2. By Drug Class 16.20.2.3. By Treatment 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Disease Type 17.3.3. By Drug Class 17.3.4. By Treatment 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. B. Braun Melsungen AG 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Beckman Coulter Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Baxter International Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. ChemoCentryx Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Dimerix Ltd 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Medtronic PLC 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Pfizer Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Mylan N.V. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Amgen Inc. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. AstraZeneca plc 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market
